Name: 8th Edition MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference ( Time Zone - CENTRAL EUROPEAN TIME (CET)
Start: 2021-03-24
End: 2021-03-26

CONFERENCE AGENDA

Registration	13:15 - 13:50
Welcome note from MarketsandMarkets	13:50 - 13:55
Opening Remarks from the Chairman George Pell, CEO and Founder, Thirty-Six	13:55 - 14:00
Keynote Presentation: PD-1 Antibodies Either as Precision Medicine Informed Monotherapy or Combinations are Transforming Cancer Care Roy Baynes, Executive Vice President, Chief Medical Officer, Eikon Therapeutics	14:00 - 14:30
CLINICAL BIOMARKER IDENTIFICATION, QUALIFICATION AND PRECISION MEDICINE
Non-invasive Biomarker Discovery and Clinical Investigation Using Breath Biopsy® Marc van der Schee, Head, Clinical and Translational Science, Owlstone Medical Ltd	14:30 - 15:00
Alarmins as prognostic and predictive biomarkers Francesc Mitjans, Chief Scientific Officer, Lykera Biomed, Spain	15:00 - 15:30
Capturing, Curating, and Creating Analytics Tools and Response Predictions for Clinical Diagnostics and Predictive Biomarkers in Oncology Mark Gramling, PhD, Director, Oncology, Larvol	15:30 - 16:00
Exosome-based digital PCR for FGFR testing in bladder cancer Dr. Ronny Kellner, Senior Scientist, dPCR Assay Development, QIAGEN, Germany	16:00 - 16:30
Networking and One-on-One Meetings on the event portal	16:30 - 16:45
Osteopontin: a diagnostic and differentiating factor for endometrial cancer, the driver of cell migration and invasive capacity? Deyarina Gonzalez, Professor, Molecular Medicine , Swansea University Medical School, UK	16:45 - 17:15
Enhancing Efficacy and Safety of 4-1BB Agonism with PRS-343, a Tumor-Targeted Bispecific Markus Zettl, Director, Immuno-Oncology , Pieris Pharmaceuticals, Germany	17:15 - 17:45
Cytoskeletal remodelling as a hallmark of cancer aggressiveness Victoria Sanz-Moreno , Professor, Cancer Cell Biology , Cancer Research UK Barts Centre, UK	17:45 - 18:15
Multiplex Analysis of the Immune Microenvironment in Tissue Biopsies Keith Wharton, VP, Medical Director, Ultivue, USA	18:15 - 18:45
Closing Remarks from the Chairman	18:45 - 18:50
End of Day 1 and Networking and One-on-One Meetings on the event portal	18:50 - 18:50

Registration	13:15 - 13:50
Welcome note from MarketsandMarkets	13:50 - 13:55
Opening Remarks from the Chairman George Pell, CEO and Founder, Thirty-Six	13:55 - 14:00
Keynote Presentation: Preclinical Application of Tissue Imaging Technology In Cancer Immunotherapy Discovery Darell Borger, Associate Director, Translational Oncology, Takeda Pharmaceuticals, USA	14:00 - 14:30
TRANSLATIONAL AND CLINICAL BIOMARKER DRUG DISCOVERY AND ASSAY DEVELOPMENT
FirePlex® multiplexed assay platform - A Biomarker Discovery Tool Zev Gechtman , Ph.D. Technical Product Manager, Abcam	14:30 - 15:00
Assessing functional antibody affinity and memory B cell abundance using the ImmunoSpot® platform Greg Kirchenbaum, Senior Scientist, Cellular Technology Limited, USA	15:00 - 15:30
Untargeted Drug Biomarker Discovery & Distribution for (Early) Safety and Target Engagement by MALDI Tissue Mass Spectrometry Imaging: An Underestimated Tool in Drug Discovery Bogdan Munteanu, Lab Head, Global Imaging Mass Spectrometry Biomarker Discovery Platform (DMPK), Sanofi, Germany	15:30 - 16:00
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	16:00 - 16:30
Networking and One-on-One Meetings on the event portal	16:30 - 16:45
Emerging technologies for interrogation of blood-based cancer biomarkers Emmanouil Karteris, Reader in Biomedical Sciences, Brunel University	16:45 - 17:15
Increasing the Targeting Specificity of Immunotherapeutics Colin Self , CEO, Precision ImmunoTherapeutics	17:15 - 17:45
Development of Antibodies for breast cancer therapeutic and diagnostic applications based on a biological marker of recurrence Ginette Serrero, Chief Executive Officer, A&G Pharmaceutical, Inc. \| Precision Antibody	17:45 - 18:15
Building a cutting-edge platform for translational research on x-omics and digital pathology data Eike Staub, Head, Oncology Bioinformatics, Merck Healthcare, Germany	18:15 - 18:45
Closing Remarks from the Chairman	18:45 - 18:50
End of Day 2 and Networking and One-on-One Meetings on the event portal	18:50 - 18:50

Registration	13:15 - 13:50
Welcome note from MarketsandMarkets	13:50 - 13:55
Opening Remarks from the Chairman George Pell, CEO and Founder, Thirty-Six	13:55 - 14:00
Keynote Presentation : Targeted therapy and companion diagnostic development in a pharma-Dx partnership case study Anna Pokorska-Bocci, Associate Principal Scientist, Debiopharm, Switzerland	14:00 - 14:30
COMMERCIALIZING BIOMARKERS IN COMPANION DIAGNOSTIC APPLICATIONS
Into the weeds of CDx commercialization: An oncology reference laboratory perspective Scott Reid, Vice President, Alliances & CDx., Neogenomics	14:30 - 15:00
Slide-Based Multiplexing Biomarker Assays for Companion Diagnostics	15:00 - 15:30
Companion Diagnostics in Immuno-Oncology: Global Commercial and Partnership Considerations Mark Girardi, Senior Vice President, Boston Healthcare, USA	15:30 - 16:00
Utilization of Limited Sample Availability in Biomarker Discovery and CDx BJ Kerns, Vice President, Scientific Collaborations , HTG Molecular Diagnostics	16:00 - 16:30
Networking and One-on-One Meetings on the event portal	16:30 - 16:45
Preparing for FGFR CDx testing in support of a new drug in bladder cancer: a Day-One case study Dr. Reinhard Ortmann, Director Oncology & Precision Diagnostics, QIAGEN, Germany	16:45 - 17:15
Closing Remarks from the Chairman	17:15 - 17:20
End of Conference	17:20 - 17:20